RGEN

RGEN

USD

Repligen Corporation Common Stock

$146.930-2.130 (-1.429%)

Precio en Tiempo Real

Healthcare
Medical Instruments & Supplies
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$149.060

Máximo

$151.250

Mínimo

$146.000

Volumen

0.61M

Fundamentos de la Empresa

Capitalización de Mercado

8.3B

Industria

Medical Instruments & Supplies

País

United States

Estadísticas de Negociación

Volumen Promedio

0.92M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $102.97Actual $146.930Máximo $182.52

Noticias Relacionadas

GlobeNewswire

Repligen Corporation to Present at Upcoming November Conferences

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming

Ver más
Repligen Corporation to Present at Upcoming November Conferences
Analyst Upgrades

Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $165

Canaccord Genuity analyst Kyle Mikson maintains Repligen with a Hold and raises the price target from $150 to $165.

Ver más
Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $165
Analyst Upgrades

Barclays Maintains Overweight on Repligen, Raises Price Target to $175

Barclays analyst Luke Sergott maintains Repligen with a Overweight and raises the price target from $160 to $175.

Ver más
Barclays Maintains Overweight on Repligen, Raises Price Target to $175
GlobeNewswire

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchisesOrders increased sequentially and greater than 20% year-over-yearIncreasing

Ver más
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
GlobeNewswire

Repligen to Report Third Quarter 2025 Financial Results

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2025 financial results on Tuesday, October 28, 2025. The Company will

Ver más
Repligen to Report Third Quarter 2025 Financial Results

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.